Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer

Masayuki Hiraki, Junichi Nishimura, Hidekazu Takahashi, Xin Wu, Yusuke Takahashi, Masaaki Miyo, Naohiro Nishida, Mamoru Uemura, Taishi Hata, Ichiro Takemasa, Tsunekazu Mizushima, Jae Won Soh, Yuichiro Doki, Masaki Mori, Hirofumi Yamamoto

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional relevance of miRNAs in mutant KRAS cancers, we transfected exogenous KRAS G12V into human embryonic kidney 293 and MRC5 cells with wild-type KRAS and BRAF genes, and we comprehensively profiled the dysregulated miRNAs. The result showed that mature miRNA oligonucleotide (miR)-4689, one of the significantly down-regulated miRNAs in KRAS G12V overexpressed cells, was found to exhibit a potent growth-inhibitory and proapoptotic effect both in vitro and in vivo. miR-4689 expression was significantly down-regulated in cancer tissues compared to normal mucosa, and it was particularly decreased in mutant KRAS CRC tissues. miR-4689 directly targets v-ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS) and v-akt murine thymoma viral oncogene homolog 1(AKT1), key components of two major branches in EGFR pathway, suggesting KRAS overdrives this signaling pathway through inhibition of miR-4689. Overall, this study provided additional evidence that mutant KRAS functions as a broad regulator of the EGFR signaling cascade by inhibiting miR-4689, which negatively regulates both RAS/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT pathways. These activities indicated that miR-4689 may be a promising therapeutic agent in mutant KRAS CRC.

Original languageEnglish
Article numbere231
Pages (from-to)e231
JournalMolecular Therapy - Nucleic Acids
Volume4
Issue number3
DOIs
Publication statusPublished - Mar 1 2015
Externally publishedYes

Fingerprint

MicroRNAs
Colorectal Neoplasms
Oligonucleotides
Epidermal Growth Factor Receptor
Therapeutics
Oncogenes
MAP Kinase Kinase 3
Molecular Targeted Therapy
Neoplasms
1-Phosphatidylinositol 4-Kinase
Thymoma
Gene Regulatory Networks
Drug Resistance
Sarcoma
Mucous Membrane
Kidney
Mutation
Growth

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery

Cite this

Hiraki, M., Nishimura, J., Takahashi, H., Wu, X., Takahashi, Y., Miyo, M., ... Yamamoto, H. (2015). Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer. Molecular Therapy - Nucleic Acids, 4(3), e231. [e231]. https://doi.org/10.1038/mtna.2015.5

Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer. / Hiraki, Masayuki; Nishimura, Junichi; Takahashi, Hidekazu; Wu, Xin; Takahashi, Yusuke; Miyo, Masaaki; Nishida, Naohiro; Uemura, Mamoru; Hata, Taishi; Takemasa, Ichiro; Mizushima, Tsunekazu; Soh, Jae Won; Doki, Yuichiro; Mori, Masaki; Yamamoto, Hirofumi.

In: Molecular Therapy - Nucleic Acids, Vol. 4, No. 3, e231, 01.03.2015, p. e231.

Research output: Contribution to journalArticle

Hiraki, M, Nishimura, J, Takahashi, H, Wu, X, Takahashi, Y, Miyo, M, Nishida, N, Uemura, M, Hata, T, Takemasa, I, Mizushima, T, Soh, JW, Doki, Y, Mori, M & Yamamoto, H 2015, 'Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer', Molecular Therapy - Nucleic Acids, vol. 4, no. 3, e231, pp. e231. https://doi.org/10.1038/mtna.2015.5
Hiraki, Masayuki ; Nishimura, Junichi ; Takahashi, Hidekazu ; Wu, Xin ; Takahashi, Yusuke ; Miyo, Masaaki ; Nishida, Naohiro ; Uemura, Mamoru ; Hata, Taishi ; Takemasa, Ichiro ; Mizushima, Tsunekazu ; Soh, Jae Won ; Doki, Yuichiro ; Mori, Masaki ; Yamamoto, Hirofumi. / Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer. In: Molecular Therapy - Nucleic Acids. 2015 ; Vol. 4, No. 3. pp. e231.
@article{48a33977bdc3452db7ca36fbb41ef725,
title = "Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer",
abstract = "KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional relevance of miRNAs in mutant KRAS cancers, we transfected exogenous KRAS G12V into human embryonic kidney 293 and MRC5 cells with wild-type KRAS and BRAF genes, and we comprehensively profiled the dysregulated miRNAs. The result showed that mature miRNA oligonucleotide (miR)-4689, one of the significantly down-regulated miRNAs in KRAS G12V overexpressed cells, was found to exhibit a potent growth-inhibitory and proapoptotic effect both in vitro and in vivo. miR-4689 expression was significantly down-regulated in cancer tissues compared to normal mucosa, and it was particularly decreased in mutant KRAS CRC tissues. miR-4689 directly targets v-ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS) and v-akt murine thymoma viral oncogene homolog 1(AKT1), key components of two major branches in EGFR pathway, suggesting KRAS overdrives this signaling pathway through inhibition of miR-4689. Overall, this study provided additional evidence that mutant KRAS functions as a broad regulator of the EGFR signaling cascade by inhibiting miR-4689, which negatively regulates both RAS/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT pathways. These activities indicated that miR-4689 may be a promising therapeutic agent in mutant KRAS CRC.",
author = "Masayuki Hiraki and Junichi Nishimura and Hidekazu Takahashi and Xin Wu and Yusuke Takahashi and Masaaki Miyo and Naohiro Nishida and Mamoru Uemura and Taishi Hata and Ichiro Takemasa and Tsunekazu Mizushima and Soh, {Jae Won} and Yuichiro Doki and Masaki Mori and Hirofumi Yamamoto",
year = "2015",
month = "3",
day = "1",
doi = "10.1038/mtna.2015.5",
language = "English",
volume = "4",
pages = "e231",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer

AU - Hiraki, Masayuki

AU - Nishimura, Junichi

AU - Takahashi, Hidekazu

AU - Wu, Xin

AU - Takahashi, Yusuke

AU - Miyo, Masaaki

AU - Nishida, Naohiro

AU - Uemura, Mamoru

AU - Hata, Taishi

AU - Takemasa, Ichiro

AU - Mizushima, Tsunekazu

AU - Soh, Jae Won

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Yamamoto, Hirofumi

PY - 2015/3/1

Y1 - 2015/3/1

N2 - KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional relevance of miRNAs in mutant KRAS cancers, we transfected exogenous KRAS G12V into human embryonic kidney 293 and MRC5 cells with wild-type KRAS and BRAF genes, and we comprehensively profiled the dysregulated miRNAs. The result showed that mature miRNA oligonucleotide (miR)-4689, one of the significantly down-regulated miRNAs in KRAS G12V overexpressed cells, was found to exhibit a potent growth-inhibitory and proapoptotic effect both in vitro and in vivo. miR-4689 expression was significantly down-regulated in cancer tissues compared to normal mucosa, and it was particularly decreased in mutant KRAS CRC tissues. miR-4689 directly targets v-ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS) and v-akt murine thymoma viral oncogene homolog 1(AKT1), key components of two major branches in EGFR pathway, suggesting KRAS overdrives this signaling pathway through inhibition of miR-4689. Overall, this study provided additional evidence that mutant KRAS functions as a broad regulator of the EGFR signaling cascade by inhibiting miR-4689, which negatively regulates both RAS/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT pathways. These activities indicated that miR-4689 may be a promising therapeutic agent in mutant KRAS CRC.

AB - KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional relevance of miRNAs in mutant KRAS cancers, we transfected exogenous KRAS G12V into human embryonic kidney 293 and MRC5 cells with wild-type KRAS and BRAF genes, and we comprehensively profiled the dysregulated miRNAs. The result showed that mature miRNA oligonucleotide (miR)-4689, one of the significantly down-regulated miRNAs in KRAS G12V overexpressed cells, was found to exhibit a potent growth-inhibitory and proapoptotic effect both in vitro and in vivo. miR-4689 expression was significantly down-regulated in cancer tissues compared to normal mucosa, and it was particularly decreased in mutant KRAS CRC tissues. miR-4689 directly targets v-ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS) and v-akt murine thymoma viral oncogene homolog 1(AKT1), key components of two major branches in EGFR pathway, suggesting KRAS overdrives this signaling pathway through inhibition of miR-4689. Overall, this study provided additional evidence that mutant KRAS functions as a broad regulator of the EGFR signaling cascade by inhibiting miR-4689, which negatively regulates both RAS/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT pathways. These activities indicated that miR-4689 may be a promising therapeutic agent in mutant KRAS CRC.

UR - http://www.scopus.com/inward/record.url?scp=84958534027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958534027&partnerID=8YFLogxK

U2 - 10.1038/mtna.2015.5

DO - 10.1038/mtna.2015.5

M3 - Article

VL - 4

SP - e231

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

SN - 2162-2531

IS - 3

M1 - e231

ER -